EP Patent

EP3081198A1 — Elektroporation device for the eye with a support and with a needle electrode

Assigned to Eyevensys · Expires 2016-10-19 · 10y expired

What this patent protects

The present application relates to an electroporation device for injecting a product into a ciliary muscle of an eye, said device comprising: - a support (16) having a support contact surface (18) extending along a virtual sphere (S) having a radius between 10 and 15 mm, so as t…

USPTO Abstract

The present application relates to an electroporation device for injecting a product into a ciliary muscle of an eye, said device comprising: - a support (16) having a support contact surface (18) extending along a virtual sphere (S) having a radius between 10 and 15 mm, so as to match the outside surface of an eye, - a first electrode (10) comprising an invasive electrode needle, - a second electrode having an electrically conductive electrode contact surface and - optionally an injection needle, wherein the support comprises an insertion guide (28) configured to guide a sliding of said electrode needle and/or injection needle along a respective insertion axis (Δ 28 ), so that the angle between said insertion axis and a plane tangential to the virtual sphere at the insertion point (P i ) is less than 40°, the insertion point being the point where said insertion axis crosses said virtual sphere.

Drugs covered by this patent

Patent Metadata

Patent number
EP3081198A1
Jurisdiction
EP
Classification
Expires
2016-10-19
Drug substance claim
No
Drug product claim
No
Assignee
Eyevensys
Source
FDA Orange Book + USPTO grounding via Google Patents

Bibliographic data sourced from FDA Orange Book + USPTO public records. Plain-English summary generated by AI grounded in source text. Patent term extensions (PTR, SPC, pediatric) may shift the effective expiry. Not legal advice.

Track this patent

Get a daily-checked alert when vulnerability score, expiry, classification, or assignee changes. Email, Slack, or Teams delivery. Pro: 50 watches, Free: 3.